OVID Ovid Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1636651 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-78.0%
TTM net income YoY-18.7%
TTM EPS YoY—
Revenue 3-yr CAGR69.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-4,700.3%
Net margin-2,971.3%
FCF margin—
EBITDA margin-4,694.6%
Returns
ROE-35.4%
ROA-30.1%
ROIC (approx.)-52.1%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets10.6%
Debt / equity0.00x
Current ratio11.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.34x
Accruals ratio10.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $733,000 | $0 | $718,000 | $132,000 | $6.27M | $130,000 | $76,000 |
| R&D expense | $15.70M | $9.96M | $11.18M | $6.59M | $5.87M | $6.46M | $6.66M | $5.92M |
| SG&A expense | $6.67M | $6.47M | $6.67M | $6.42M | $6.79M | $4.88M | $6.02M | $4.88M |
| Operating income | -$22.36M | -$15.70M | -$17.85M | -$12.29M | -$12.52M | -$5.07M | -$12.55M | -$10.72M |
| Pretax income | -$20.78M | -$15.01M | -$16.99M | $9.66M | -$12.16M | -$4.68M | -$10.23M | -$9.25M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$20.78M | -$15.01M | -$16.99M | $9.66M | -$12.16M | -$4.68M | -$10.23M | -$9.25M |
| EBITDA | -$22.35M | -$15.68M | -$17.81M | -$12.28M | -$12.51M | -$5.01M | -$12.41M | -$10.56M |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $13.81M | $11.33M | $94.06M | $13.15M | $22.54M | $30.35M | $23.07M | $28.23M |
| Short-term investments | $122.79M | $105.89M | $61.46M | $56.48M | $4.99M | $9.93M | $21.86M | $26.77M |
| Current assets | $141.96M | $123.62M | $160.15M | $74.37M | $28.82M | $42.09M | $45.92M | $55.94M |
| PP&E, net | $186,000 | $201,000 | $217,000 | $252,000 | $269,000 | $285,000 | $346,000 | $433,000 |
| Intangibles | $0 | $0 | $0 | $0 | $0 | $0 | $38,000 | $100,000 |
| Total assets | $222.24M | $231.97M | $225.63M | $150.93M | $63.85M | $77.43M | $81.65M | $92.17M |
| Current liabilities | $11.86M | $9.98M | $15.75M | $8.29M | $6.80M | $8.92M | $9.31M | $10.52M |
| Total liabilities | $23.57M | $22.08M | $27.36M | $20.27M | $19.15M | $21.64M | $22.38M | $23.94M |
| Shareholders' equity | $198.67M | $209.89M | $198.27M | $130.66M | $44.70M | $55.79M | $59.28M | $68.23M |
| Shares outstanding | 188.72M | 184.76M | 167.27M | 130.18M | 71.15M | 71.11M | 71.11M | 71.01M |
| Cash flow statement | ||||||||
| Operating cash flow | -$15.88M | -$17.59M | -$13.90M | -$10.41M | -$12.87M | -$4.77M | -$10.28M | -$10.01M |
| Capital expenditure | — | — | — | $0 | $0 | $0 | $0 | $22,000 |
| Free cash flow | — | — | — | -$10.41M | -$12.87M | -$4.77M | -$10.28M | -$10.03M |
| Investing cash flow | $11.15M | -$86.74M | $5.95M | -$72.06M | $5.05M | $12.05M | $5.10M | $21.29M |
| Financing cash flow | $7.28M | $21.60M | $88.98M | $75.18M | $15,000 | $0 | $13,000 | $0 |
| Depreciation & amortization | $15,000 | $16,000 | $35,000 | $17,000 | $17,000 | $61,000 | $141,000 | $160,000 |
| Stock-based compensation | $1.28M | $1.43M | $1.05M | $1.20M | $1.11M | $1.22M | $1.28M | $1.26M |
Free plan shows the latest 8 periods; Pro shows all 43 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.